Aegis Capital Reinstates Coverage on BiondVax Pharmaceuticals With Buy Rating, $7 Price Target

Published on 01/26/2022 at 11:53 - Modifié on 01/26/2022 at 11:54

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd. announced that it has received $1.38 million in funding from Yorkville Advisors Global LP	Jun. 11	CI
Scinai Immunotherapeutics Ltd. - Special Call	May. 07
Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	May. 07	CI
Scinai Immunotherapeutics Ltd. Auditor Raises 'Going Concern' Doubt	May. 06	CI
Top Midday Decliners	Mar. 27	MT
Scinai Immunotherapeutics Signs Option Deal to Acquire Italy's Pincell	Mar. 27	MT
Carlo Pincelli to Join Scinai Immunotherapeutics Ltd.'s Scientific Advisory Board and Management Team of Pincell to Join Scinai's Wholly Owned, Newly Created Subsidiary in Poland	Mar. 27	CI
Scinai Immunotherapeutics Ltd. Enters into License Agreement with an Affiliated U.S. Private Company	Mar. 24	CI
Scinai Immunotherapeutics Ltd. Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc	Dec. 16	CI
Scinai Immunotherapeutics Ltd. Appoints Michael Schön to Its Scientific Advisory Board	Dec. 05	CI
Scinai Immunotherapeutics Ltd. Appoints Jonathan Sadeh as Member of Scientific Advisory Board	Nov. 27	CI
Earnings Flash (SCNI) SCINAI IMMUNOTHERAPEUTICS Reports Q3 Revenue $168,000	Nov. 22	MT
Earnings Flash (SCNI) SCINAI IMMUNOTHERAPEUTICS Reports Q3 Revenue $168,000	Nov. 22	MT
Earnings Flash (SCNI) SCINAI IMMUNOTHERAPEUTICS Reports Q3 Revenue $168,000	Nov. 22	MT
Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 22	CI
Scinai Immunotherapeutics Ltd. Enters into License Agreement with Unaffiliated U.S. Private Company	24-09-26	CI
Scinai Immunotherapeutics Ltd. - Special Call	24-09-18
Scinai Immunotherapeutics Ltd., Q2 2024 Earnings Call, Aug 20, 2024	24-08-20
Scinai Immunotherapeutics Signs $2 Million Investment Commitment Deal; Shares Rise	24-08-20	MT
Scinai Immunotherapeutics Ltd. announced that it expects to receive $2 million in funding	24-08-19	CI
Scinai Immunotherapeutics Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	24-08-15	CI
Sector Update: Health Care Stocks Edge Lower Late Afternoon	24-07-15	MT
Scinai Immunotherapeutics Ltd. Announces Successful In-Vivo Preclinical Study Results of Its Innovative Anti IL-17A/F VHH Antibody Fragment	24-07-15	CI
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday as Investors Bet on a Trump Win	24-07-15	MT
Top Premarket Gainers	24-07-15	MT

SCINAI IMMUNOTHERAPEUTICS LTD.

Stock

SCNI

US09073Q3039

Market Closed - Nasdaq Other stock markets 04:30:00 2025-07-15 pm EDT
2.220 ^USD	-3.48%

More quotes

Chart

Duration

Period

SCNI: Dynamic Chart

Income Statement and Estimates

More financial data

Headlines

Rare earths: Apple joins the industrial front supported by the Pentagon

Is Scott Bessent the ideal candidate to succeed Jerome Powell?

July 16, 2025 at 06:06 am EDT

Rio Tinto posts strongest iron ore output since 2018 amid executive shake-up

July 16, 2025 at 04:08 am EDT

What if we already knew the name of Apple's next CEO?

July 16, 2025 at 03:21 am EDT

A Scandinavian consortium acquires Dalata for EUR1.4bn

July 15, 2025 at 10:04 am EDT

Mexican tomatoes: Made in the USA or higher prices, the Trump dilemma

July 15, 2025 at 09:56 am EDT

Meta to spend hundreds of billions on data centers

July 15, 2025 at 07:00 am EDT

Chinese growth exceeds expectations in second quarter, but uncertainties remain

July 15, 2025 at 06:56 am EDT

Nvidia announces the return of its chips to China

July 15, 2025 at 06:49 am EDT

The renovation of Fed's headquarters: a new means of pressure from White House on Jerome Powell

July 15, 2025 at 04:59 am EDT

All our articles